[A26-97] Inebilizumab (immunoglobulin G4-related disease) – Addendum to Project A26-26
Last updated 03.09.2026
Project no.:
A26-97
Commission:
Commission awarded on 28.07.2026 by the Federal Joint Committee (GBA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Adults with active immunoglobulin G4-related disease for whom long-term immunosuppressive treatment is an option
Result of dossier assessment:
unchanged after addendum: Added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-97
| Project no. | Title | Status |
|---|---|---|
| A26-26 | Inebilizumab (immunoglobulin G4-related disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
03-09-2026 A G-BA decision was published.
G-BA documents on this decision